Viridian Therapeutics (NASDAQ:VRDN) shares shot up 25% in early trading Monday after the company reported positive topline results from a Phase 3 study of its drug veligrotug in the treatment of ...

Viridian Odyssey is a timeless blue-green hue. Dunn-Edwards has been announcing a Color of the Year since 2017, but the paint company just unveiled its first-ever Color of the Century—Viridian Odyssey ...

WALTHAM, Mass., January 08, 2025--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare ...

Thyroid eye disease (TED) therapy Tepezza – the biggest asset in Amgen's $26 billion takeover of Horizon last year – could soon face competition from a drug in the same class from Viridian ...

Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Viridian Therapeutics (VRDN – Research Report) today and set a price ...

Viridian Metals (TSXV: VRDN) announced Friday it has expanded its land position in Canada’s Labrador through staking, securing 2,600 km² of the prospective Seal Basin. This newly acquired ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...